CD274 and breast carcinoma: Several of these inhibitor agents have been investigated for targeting in breast cancer (PD-1 inhibitors: pembrolizumab and nivolumab; PD-L1 inhibitors: atezolizumab, avelumab, and durvalumab; CTLA-4 inhibitor: ipilimumab and tremelimumab).